Sonoma Pharmaceuticals Inc./$SNOA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Ticker
$SNOA
Sector
Primary listing
Employees
8
Headquarters
Website
SNOA Metrics
BasicAdvanced
$6.7M
-
-$2.47
1.47
-
Price and volume
Market cap
$6.7M
Beta
1.47
52-week high
$6.92
52-week low
$1.75
Average daily volume
60K
Financial strength
Current ratio
2.704
Quick ratio
1.328
Long term debt to equity
10.848
Total debt to equity
16.642
Profitability
EBITDA (TTM)
-3.497
Gross margin (TTM)
37.71%
Net profit margin (TTM)
-23.84%
Operating margin (TTM)
-24.36%
Effective tax rate (TTM)
-12.79%
Revenue per employee (TTM)
$1,860,000
Management effectiveness
Return on assets (TTM)
-16.06%
Return on equity (TTM)
-78.73%
Valuation
Price to revenue (TTM)
0.393
Price to book
1.65
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-4.267
Free cash flow yield (TTM)
-23.43%
Free cash flow per share (TTM)
-0.954
Growth
Revenue change (TTM)
17.43%
Earnings per share change (TTM)
-67.15%
3-year revenue growth (CAGR)
4.88%
10-year revenue growth (CAGR)
0.53%
3-year earnings per share growth (CAGR)
-58.11%
10-year earnings per share growth (CAGR)
-44.10%
SNOA News
AllArticlesVideos
Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
Accesswire7 days ago
Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Accesswire3 weeks ago
National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced
Accesswire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sonoma Pharmaceuticals Inc. stock?
Sonoma Pharmaceuticals Inc. (SNOA) has a market cap of $6.7M as of October 14, 2025.
What is the P/E ratio for Sonoma Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for Sonoma Pharmaceuticals Inc. (SNOA) stock is 0 as of October 14, 2025.
Does Sonoma Pharmaceuticals Inc. stock pay dividends?
No, Sonoma Pharmaceuticals Inc. (SNOA) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Sonoma Pharmaceuticals Inc. dividend payment date?
Sonoma Pharmaceuticals Inc. (SNOA) stock does not pay dividends to its shareholders.
What is the beta indicator for Sonoma Pharmaceuticals Inc.?
Sonoma Pharmaceuticals Inc. (SNOA) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.